Sweden

Diamyd Medical AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CFRT 2020

Participation Not Confirmed

Update your events

Phase IIb Topline Results Demonstrate a Significant Treatment Effect of Diamyd® in Type 1 Diabetes

Lead Product(s): GAD-alum

Therapeutic Area: Endocrinology Product Name: Diamyd

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 14, 2020

Details:

In line with previous large-scale analysis of trials involving subcutaneous administration of Diamyd®, the reults, encompassing a total of 109 patients, showed a statistically significant effect in the predefined HLA (Human Leukocyte Antigen) subgroup of trial participants.

Diamyd Medical AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CFRT 2020

Participation Not Confirmed

Update your events

Diamyd Medical's Analysis of Prevention Trials and Intralymphatic Pilot Trial with the Diabetes Vaccine Diamyd® Support a Positive Trend in...

Lead Product(s): GAD-alum

Therapeutic Area: Endocrinology Product Name: Diamyd

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 01, 2020

Details:

The analysis while not reaching statistical significance, supports a positive effect of subcutaneous injections of Diamyd® on delaying the progression to type 1 diabetes in HLA-type DR3-DQ2 group while no benefit vs placebo is seen in individuals negative for HLA-type DR3-DQ2.

Diamyd Medical AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CFRT 2020

Participation Not Confirmed

Update your events

Diabetologia Publishes Results Highlighting Efficacy of the Diabetes Vaccine Diamyd® in Genetically Defined Subgroups of Type 1 Diabetes

Lead Product(s): GAD-alum

Therapeutic Area: Endocrinology Product Name: Diamyd

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

Details:

Diabetologia published results from a meta study that demonstrates a highly significant and clinically relevant effect of Diamyd Medical's lead drug candidate Diamyd® on preserving endogenous insulin production in genetically defined subgroups of type 1 diabetes.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Diamyd Medical AB

Phase IIb Topline Results Demonstrate a Significant Treatment Effect of Diamyd® in Type 1 Diabetes

Diamyd Medical AB

Diamyd Medical's Analysis of Prevention Trials and Intralymphatic Pilot Trial with the Diabetes Vaccine Diamyd® Support a Positive Trend in...

Diamyd Medical AB

Diabetologia Publishes Results Highlighting Efficacy of the Diabetes Vaccine Diamyd® in Genetically Defined Subgroups of Type 1 Diabetes